Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8253)
All Articles published online
|
Publishing Process of This Article
|
Apr 7, 2020 (publication date) through Jan 30, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wu FP, Yang Y, Li M, Liu YX, Li YP, Wang WJ, Shi JJ, Zhang X, Jia XL, Dang SS. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study. World J Gastroenterol 2020; 26(13): 1525-1539 [PMID: 32308352 DOI: 10.3748/wjg.v26.i13.1525] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v26/i13/1525.htm |
| Number | Citing Articles |
| 1 |
Pei-Xin Zhang, Qian-Qian Tang, Jie Zhu, Wan-Yu Deng, Zhen-Hua Zhang. Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis. Hepatology International 2024; 18(4): 1110 doi: 10.1007/s12072-024-10666-6
|
| 2 |
Bo Feng, Jia-Rui Zheng. Importance of quantitative HBsAg detection in whole course management of patients with chronic hepatitis B. World Chinese Journal of Digestology 2022; 30(15): 655 doi: 10.11569/wcjd.v30.i15.655
|
| 3 |
Wencong Zhang, Mingyou Xing, Wenjin Sun, Jia Chen, Nana Xie, Yuan Cai, Ying Wang, Niuniu Li, Yujin Jiang, Fan Zhang, Yanfeng Wang, Qingjin Zeng, Yanhua Ji, Cheng Xu, Chunmei Jiang, Jianxin Song, Guojun Li. Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: A real‐world analysis. Journal of Viral Hepatitis 2023; 30(5): 427 doi: 10.1111/jvh.13792
|
| 4 |
Yuying Li, Siqi Yang, Cong Li, Zhenjie Ma, Mengmeng Zhang, Wenhang Zou, Zihao Wu, Haiyan Hou, Weixing Wang, Liying Zhu. Efficacy of short-term Peg-IFN α-2b treatment in chronic hepatitis B patients with ultra-low HBsAg levels: a retrospective cohort study. Virology Journal 2024; 21(1) doi: 10.1186/s12985-024-02512-w
|
| 5 |
Qian-Guo Mao, Hui-Qing Liang, Ya-Lin Yin, Jin-Mo Tang, Jia-En Yang, Chun-Cheng Wu, Yue Chen, Man-Ying Zhang, Yao-Yu Liu, Xiao-Ting Zheng, Lin-Yi Zhuang, Shao-Dong Chen. Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B. Clinics and Research in Hepatology and Gastroenterology 2022; 46(1): 101758 doi: 10.1016/j.clinre.2021.101758
|
| 6 |
Wen-Xin Wang, Rui Jia, Ying-Ying Gao, Jia-Ye Liu, Jun-Qing Luan, Fei Qiao, Li-Min Liu, Xiao-Ning Zhang, Fu-Sheng Wang, Junliang Fu. Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.894410
|
| 7 |
Ya-mei Ye, Yong Lin, Fang Sun, Wen-yan Yang, Lina Zhou, Chun Lin, Chen Pan. A predictive model for functional cure in chronic HBV patients treated with pegylated interferon alpha: a comparative study of multiple algorithms based on clinical data. Virology Journal 2024; 21(1) doi: 10.1186/s12985-024-02599-1
|
| 8 |
Fei Yan, Fei Tang, Jing Chen, YiCheng Lin, XinYu Chen, Qin Du, WeiLi Yin, Jing Liang, Lei Liu, Fang Wang, BaiGuo Xu, Qing Ye, HuiLing Xiang. Exploring using HBsAg to predict interferon treatment course to achieve clinical cure in chronic hepatitis B patients: a clinical study. Frontiers in Immunology 2025; 15 doi: 10.3389/fimmu.2024.1528758
|
| 9 |
Fengping Wu, Rui Lu, Yixin Liu, Yikai Wang, Yan Tian, Yaping Li, Mei Li, Wenjun Wang, Xin Zhang, Xiaoli Jia, Shuangsuo Dang. Efficacy and safety of peginterferon alpha monotherapy in Chinese inactive chronic hepatitis B virus carriers. Liver International 2021; 41(9): 2032 doi: 10.1111/liv.14897
|
| 10 |
Wattana Leowattana, Pathomthep Leowattana, Tawithep Leowattana. Quantitative hepatitis B core antibody and quantitative hepatitis B surface antigen: Novel viral biomarkers for chronic hepatitis B management. World Journal of Hepatology 2024; 16(4): 550-565 doi: 10.4254/wjh.v16.i4.550
|
| 11 |
Xiaoan Yang, Ka Zhang, Qihuan Xu, Xin Shu, Zhishuo Mo, Dongying Xie, Zhiliang Gao, Hong Deng. Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAg. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.997608
|
| 12 |
Jiarui Zheng, Zilong Wang, Linxiang Huang, Zixuan Qiu, Yandi Xie, Suzhen Jiang, Bo Feng. Achieving chronic hepatitis B functional cure: Factors and potential mechanisms. Virus Research 2025; 351: 199507 doi: 10.1016/j.virusres.2024.199507
|
| 13 |
Jun‐Hao Chu, Yan Huang, Dong‐Ying Xie, Hong Deng, Jia Wei, Yu‐Juan Guan, Guo‐Jun Li, Yi‐Lan Zeng, Jia‐Hong Yang, Xin‐Yue Chen, Jia Shang, Jia‐Bin Li, Na Gao, Zhi‐Liang Gao. Real‐world study on HBsAg loss of combination therapy in HBeAg‐negative chronic hepatitis B patients. Journal of Viral Hepatitis 2022; 29(9): 765 doi: 10.1111/jvh.13722
|
| 14 |
Shuang Xu, Xiao-Ting Ye, Dong Zhang, Pu Dong, Yang-He Wu, Chen-Wei Pan. Predicting clinical outcomes in chronic hepatitis B patients receiving nucleoside analogues and pegylated interferon alpha: a hematochemical and clinical analysis. BMC Infectious Diseases 2024; 24(1) doi: 10.1186/s12879-024-10057-0
|
| 15 |
Ya-Ping Li, Chen-Rui Liu, Ling He, Shuang-Suo Dang. Hepatitis B cure: Current situation and prospects. World Journal of Hepatology 2024; 16(6): 900-911 doi: 10.4254/wjh.v16.i6.900
|
| 16 |
Shaowen Jiang, Simin Guo, Yan Huang, Yalin Yin, Jingwen Feng, Huijuan Zhou, Qing Guo, Weijing Wang, Haiguang Xin, Qing Xie. Predictors of HBsAg seroclearance in patients with chronic HBV infection treated with pegylated interferon-α: a systematic review and meta-analysis. Hepatology International 2024; 18(3): 892 doi: 10.1007/s12072-024-10648-8
|
| 17 |
Shu Zhu, Lina Wu, Yongyu Mei, Zhihua Liu, Luping Lin, Jing Yuan, Jianguo Li, Xuejun Li, Liang Peng. Prospective, multicentre, randomised controlled trial comparing the seroclearance of HBsAg between combination therapy of peg-interferon alpha and tenofovir with tenofovir monotherapy in nucleos(t)ide analogue-experienced patients with HBV-related liver fibrosis: a study protocol. BMJ Open 2021; 11(10): e049104 doi: 10.1136/bmjopen-2021-049104
|
| 18 |
Xiongyue Cao, Qiankun Hu, Wei Xu, Qiang Li, Jiming Zhang, Liang Chen, Yuxian Huang, Xun Qi. Kinetics changes in total cholesterol predict HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon‐alfa. Journal of Viral Hepatitis 2023; 30(4): 310 doi: 10.1111/jvh.13787
|
| 19 |
Mei-Juan Peng, Xiao-Qing Guo, Wei-Lu Zhang, Jing Chen, Wen Kang, Xiao-Fei Yang, Ying Guo, Ye Zhang. Effect of pegylated interferon-α2b add-on therapy on renal function in chronic hepatitis B patients: A real-world experience. Frontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.980250
|
| 20 |
Laura Iulia Grecu, Camelia Sultana, Mariana Pavel-Tanasa, Simona Maria Ruta, Mihaela Chivu-Economescu, Lilia Matei, Ramona Gabriela Ursu, Elena Iftimi, Luminita Smaranda Iancu. Non-Invasive Prediction Scores for Hepatitis B Virus- and Hepatitis D Virus-Infected Patients—A Cohort from the North-Eastern Part of Romania. Microorganisms 2023; 11(12): 2895 doi: 10.3390/microorganisms11122895
|
| 21 |
Jian Wang, Zhiyi Zhang, Li Zhu, Qing Zhang, Shaoqiu Zhang, Yifan Pan, Jiacheng Liu, Fei Cao, Tao Fan, Ye Xiong, Shengxia Yin, Xiaomin Yan, Yuxin Chen, Chuanwu Zhu, Jie Li, Xingxiang Liu, Chao Wu, Rui Huang. Association of hepatitis B core antibody level and hepatitis B surface antigen clearance in HBeAg-negative patients with chronic hepatitis B. Virulence 2024; 15(1) doi: 10.1080/21505594.2024.2404965
|
| 22 |
Man-Fung Yuen, Young-Suk Lim, Ki Tae Yoon, Tien-Huey Lim, Jeong Heo, Pisit Tangkijvanich, Won Young Tak, Vaidehi Thanawala, Daniel Cloutier, Shenghua Mao, Andre Arizpe, Andrea L Cathcart, Sneha V Gupta, Carey Hwang, Edward Gane. VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study. The Lancet Gastroenterology & Hepatology 2024; 9(12): 1121 doi: 10.1016/S2468-1253(24)00237-1
|
| 23 |
巧霞 陈. Research Progress of Pegylated Interferon Therapy for Chronic HBV Infection. Advances in Clinical Medicine 2024; 14(03): 1605 doi: 10.12677/acm.2024.143884
|
| 24 |
Zehong Wang, Xuanxuan Wang, Li Zhou, Shaoyuan Shi, Yongli Hua, Yinong Feng. Safety and efficacy of 48-week pegylated interferon-α-2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study. Frontiers in Medicine 2024; 11 doi: 10.3389/fmed.2024.1489671
|
| 25 |
朝竟 温. Predictability and Durability of Functional Cure for Chronic Hepatitis B. Advances in Clinical Medicine 2023; 13(11): 18527 doi: 10.12677/ACM.2023.13112604
|
| 26 |
Zhili Tan, Nan Kong, Qiran Zhang, Xiaohong Gao, Jia Shang, Jiawei Geng, Ruirui You, Tao Wang, Ying Guo, Xiaoping Wu, Wenhong Zhang, Lihong Qu, Fengdi Zhang. Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks. Hepatology International 2024; doi: 10.1007/s12072-024-10764-5
|
| 27 |
Fengping Wu, Yikai Wang, Dandan Cui, Yan Tian, Rui Lu, Chenrui Liu, Mei Li, Yaping Li, Ning Gao, Zicheng Jiang, Xuemei Li, Song Zhai, Xin Zhang, Xiaoli Jia, Shuangsuo Dang. Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens. Journal of Clinical Medicine 2023; 12(1): 361 doi: 10.3390/jcm12010361
|
| 28 |
Wen-Xin Wang, Rui Jia, Xue-Yuan Jin, Xiaoyan Li, Shuang-Nan Zhou, Xiao-Ning Zhang, Chun-Bao Zhou, Fu-Sheng Wang, Junliang Fu. Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1121778
|
| 29 |
Huihui Lu, Wei Yi, Fangfang Sun, Zhan Zeng, Lu Zhang, Minghui Li, Yao Xie. Comprehensive investigation of HBV-related hepatocellular carcinoma and choice of anti-HBV therapy. Biosafety and Health 2021; 3(4): 190 doi: 10.1016/j.bsheal.2021.05.001
|
| 30 |
Chaojing Wen, Yixuan Wang, Haoyue Tian, Yu Lei, Zhiyi Wang, Dachuan Cai, Zhi Zhou, Xiaofeng Shi. Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study. Frontiers in Cellular and Infection Microbiology 2024; 13 doi: 10.3389/fcimb.2023.1332232
|
| 31 |
Wenting Zhong, Lanzhi Yan, Yage Zhu, Lei Shi, Yingli He, Tianyan Chen, Jie Zheng. A high functional cure rate was induced by pegylated interferon alpha-2b treatment in postpartum hepatitis B e antigen-negative women with chronic hepatitis B virus infection: an exploratory study. Frontiers in Cellular and Infection Microbiology 2024; 14 doi: 10.3389/fcimb.2024.1426960
|
| 32 |
Yan-Qing Lv, Ru-Hua Guo, Kun-Yu Liu, Jia-Jie Li, Hui-Fan Ji. Predictive factors for clinical cure in the treatment of HBeAg(−) chronic hepatitis B or compensated cirrhosis: a prospective observational study. Frontiers in Medicine 2025; 11 doi: 10.3389/fmed.2024.1483744
|
| 33 |
Jun Chen, Min Qi, Xue-Gong Fan, Xing-Wang Hu, Cheng-Jin Liao, Li-Yuan Long, Xiao-Ting Zhao, Min Tan, Hai-Fu Li, Ruo-Chan Chen, Ze-Bing Huang, Yan Huang. Efficacy of Peginterferon alfa-2b in Nucleoside Analogue Experienced Patients with Negative HBeAg and Low HBsAg: A Non-Randomized Clinical Trial. Infectious Diseases and Therapy 2021; 10(4): 2259 doi: 10.1007/s40121-021-00497-5
|
| 34 |
Hong Li, Shan Liang, Lili Liu, Daqiong Zhou, Yali Liu, Yang Zhang, Xinyue Chen, Jing Zhang, Zhenhuan Cao. Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.1091786
|
| 35 |
Ya-Ping Li, Chen-Rui Liu, Miao Hao, Rui Lu, Shuang-Suo Dang. Clinical cure of hepatitis B: Delight and anticipation. World Chinese Journal of Digestology 2023; 31(20): 837 doi: 10.11569/wcjd.v31.i20.837
|
| 36 |
Shima Mimura, Koji Fujita, Kei Takuma, Mai Nakahara, Kyoko Oura, Tomoko Tadokoro, Joji Tani, Asahiro Morishita, Masafumi Ono, Takashi Himoto, Tsutomu Masaki. Predictors of therapeutic response to peginterferon α‑2a and nucleos(t)ide analog combination therapy for HBeAg‑negative chronic hepatitis B: 1‑year follow‑up after treatment. Experimental and Therapeutic Medicine 2023; 26(6) doi: 10.3892/etm.2023.12286
|
| 37 |
Yan Peng, Mingzhe Ma, Ting Liu, Wenmin He, Shutao Lin, Wa Zhong, Xiaohui Min. Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients treated with nucleotide analogs plus polyethylene glycol interferon. Frontiers in Medicine 2025; 11 doi: 10.3389/fmed.2024.1510230
|